Pharmacotherapy of systemic lupus erythematosus

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 9, 2009, Pages 1481-1494

  Francis, Lisa ^a   Perl, Andras ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Biological; Biomarkers; Corticosteroids; Immunosuppressive drugs; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTIMALARIAL AGENT; AZATHIOPRINE; BETAMETHASONE DIPROPIONATE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CD40 LIGAND; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; GLUTATHIONE; HYDROCORTISONE; HYDROXYCHLOROQUINE; ILOPROST; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; PREDNISONE; PROSTAGLANDIN DERIVATIVE; RITUXIMAB; STEROID; SUNSCREEN; TRIAMCINOLONE HEXACETONIDE; UNINDEXED DRUG;

ANTIPHOSPHOLIPID SYNDROME; ARTHRITIS; B LYMPHOCYTE; CORTICOSTEROID THERAPY; DISCOID LUPUS ERYTHEMATOSUS; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; HEART DISEASE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LUNG DISEASE; LUNG HEMORRHAGE; MUSCULOSKELETAL DISEASE; NONHUMAN; PERICARDITIS; PLEURISY; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES, ANTINUCLEAR; B-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 67650677014     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902971003     Document Type: Review

References (113)

1. Bombardier C, Gladman D, Unowitz MB. The development and validation of the SLE Disease Activity Index (SLEDAI). Arthritis Rheum 1992;35:630-40 •• Landmark article describing a clinical instrument to measure lupus disease activity.
2. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58 •• Landmark article describing a clinical instrument to measure lupus disease activity.
3. Tseng CE, Buyon JP, Kim M, et al. The effect of moderate dose corticosteroids in preventing severe flares in patients with serologically active but clinically stable systemic lupus erythematosus. Arthritis Rheum 2006;54:3623-3632
4. Ting WW, Sontheimer RD. Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations. Lupus 2001;10:171-184 (Pubitemid 32410073)
5. D'Cruz D. Antimalarial therapy: a panacea for mild lupus? Lupus 2001;10:148-151
6. Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatol 2004;43:1383-1385 (Pubitemid 39480924)
7. Cotell S, Robinson ND, Chan LS. Autoimmune blistering skin diseases. Am J Emerg Med 2000;18:288-299
8. Karim MY, Ruiz-Irastorza G, Khamashta MA, Hughes GRV. Update on therapy - thalidomide in the treatment of lupus. Lupus 2001;10:188-192 (Pubitemid 32410075)
9. Hiepe F, Bruns A, Feist E, Burmester GR. Successful treatment of a patient suffering from a refractory sub acute cutaneous lupus erythematosus (SCLE) with blockers of tumor necrosis factor. Arthritis Rheum 2004;50;S4131
10. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006;54:S139-42 (Pubitemid 43243490)
11. Morand EF, McCloud PI, Littlejohn GO. Continuation of long-term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1992;51:1318-1321 (Pubitemid 23000068)
12. Fox RI. Mechanism of action of hydroxychloroquine as an anti rheumatic drug. Semin Arthritis Rheum 1993;23:82-91 • Excellent review on the mechanisms of action of one of the most widely used antirheumatic drugs.
13. Kipen Y, Littlejohn GO, Morand EF. Methotrexate use in systemic lupus erythematosus. Lupus 1997;6:385-389 (Pubitemid 27232133)
14. Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001;10:162-164 (Pubitemid 32410071)
15. Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997;56:382-385 (Pubitemid 27305428)
16. Pilsoni CN, Sanchez FJ, Karim Y, et al. Mycophenolate mofetil in patients with systemic lupus erythematosus: efficacy and tolerability in 86patients. J Rheumatol 2005;32:1047-52 • Excellent original article on the safety and efficacy of Mycophenolate mofetil in patients with systemic lupus erythematosus.
17. Flanc RS, Roberts MA, Strippoli GF, et al. Treatment of lupus nephritis. Cochrane Database Syst Rev 2004;CD002922
18. Flanc RS, Roberts MA, Strippoli GF, et al. Treatment of diffuse proliferative lupus nephritis: a meta analysis of randomized controlled trials. Am J Kidney Dis 2004;43:197-208
19. Steinberg AD, Steinberg S. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arth Rheum 1991;34:945-950
20. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28 •• First study on the efficacy of Mycophenolate mofetil relative to cyclophosphamide for treatment of lupus nephritis.
21. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-257 (Pubitemid 32799338)
22. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-19 •• Landmark study on the efficacy of cyclophosphamide for treatment of lupus nephritis.
23. McCune WJ, Golbus J, Zeides W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-31 •• Landmark study on the efficacy of cyclophosphamide for treatment of severe lupus.
24. Members of the ad hoc committee on SLE Guidelines. Guidelines for referral and management of SLE in adults. Arthritis Rheum 1999;1785-1796
25. Goldblatt F, Isenberg DA. New therapies for systemic lupus erythematosus. Clin Exp Immunol 2005;140:205-212 (Pubitemid 40559146)
26. Chan TM, Li FK, Tang CS, etal. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong Guangzhou nephrology Study Group. N Engl J Med 2000;343:1156-1162
27. Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-1084 (Pubitemid 41710318)
28. Ong LM, Hooi LLS, Lim TO, et al. Randomized control trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005;10:504-510 (Pubitemid 41727277)
29. Contreras G, Nahar N, Metz D. Maintenance therapies for proliferative nephritis: mycophenolate mofetil, azathioprine and cyclophosphamide. Lupus 2005;14(Suppl):33-38 (Pubitemid 40460514)
30. Ginzler EM, Appel GB, Dooley MA, et al. Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): efficacy by racial group. ACR 2007;56:4308
31. Meissner M, Sherer Y, Levy Y, et al. Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatol Int 2000;19:199-201 (Pubitemid 30598871)
32. Robbins IM, Gaine SP, Schilz R, et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000;117:14-1831 (Pubitemid 30053613)
33. Mok MY, Tse HF, Lau CS. Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. Lupus 1999;8:328-331 (Pubitemid 29292100)
34. Ghofrani HA, Rose F, Schermuly RT, et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 2002;30:2489-2492 (Pubitemid 35351868)
35. Channick RN, Simmonneau G, Sitbon O, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study. Lancet 2001;358:1113-1114
36. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903 (Pubitemid 34984638)
37. Hochberg MC, Silman AJ, Smolen JS, et al. Rheumatology. Philadelphia: Mosby Elsevier. 2008
38. Klippel JH, Stone JH, Crofford LJ, White PH. Primer on the Rheumatic Diseases. New York: Springer. 2008
39. Ginzler EM, Dvorkina O. Newer therapeutic approaches for systemic lupus erythematosus. Rheum Dis Clin North Am 2005;31:15-328 (Pubitemid 40732491)
40. Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti CD 20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005;78:275-280 (Pubitemid 40471119)
41. Ten Cate R, Smiers FJ, Bredius RG, et al. Anti CD-20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus. Rheumatology (Oxford) 2004;43:244 (Pubitemid 38219686)
42. Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998;28:1-9 (Pubitemid 28378079)
43. Munoz-Rodriguez FJ, Font J, Cervera R, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arth Rheum 1999;29:182-190 (Pubitemid 30013282)
44. Erkan D, Harrison MH, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthritis Rheum 2007;56:2382-2391
45. Pego Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and longterm outcome of this rare manifestation of the disease. Rheumatology 2008;47:1498-1502
46. Ramos PC, Mendez MJ, Ames PR, et al. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996;14:295-299 (Pubitemid 26290870)
47. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205 [Epub 1 May 2007]
48. Miyakis S, Lockshin M, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome(APS). J Thromb Hemostasis 2006;4:295-306 •• Key publication updating the diagnostic criteria of antiphospholipid syndrome.
49. Ghaussy NO, Sibbitt W Jr, Bankhurst AD, Qualls CR. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 2003;30:1215-1221 (Pubitemid 36666343)
50. Moskovitz DN, Bodian C, Chapman ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel disease patients. Am J Gastroenterol 2004;99:656-661 (Pubitemid 38607969)
51. Smolen JS. Therapy of systemic lupus erythematosus: a look into the future. Arth Res 2002;4(Suppl 3):S25-30
52. Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation in systemic lupus erythematosus. Lupus 2004;13:168-176 (Pubitemid 38478643)
53. van Vallenhoven RF, Park JL, Genovese MC, et al. A double blind, placebo controlled clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 1999;8:181-187 (Pubitemid 29186836)
54. Chang DH, Lan JL, Lin HY, et al. Dehydroepiandrosterone treatment of women with mild to moderate systemic lupus erythematosus. A multicenter randomized, double blind, placebo controlled trial. Arthritis Rheum 2002;46:2924-2927
55. Petri MA, Lahita RG, van Vollenhaven RF, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus. Arthritis Rheum 2002;46:1820-1829
56. Arlene T, Tieng EP. B cell directed therapies in systemic lupus erythematosus. Semin Arthritis Rheum 2008;38:218-227
57. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human SLE. Arthritis Rheum 2004;50:3580-905 • Important study describing the mechanism of action of anti-CD20 treatment in SLE.
58. Garcia Carrasco M, Jimenez Hernandez M, Escarcega RO, etal. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 2008;8:343-348
59. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arth Rheum 2002;46:2673-2677 (Pubitemid 36118931)
60. Looney JR, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus. A PhaseI/II dose escalation trial of rituximab. Arth Rheum 2004;50:2580-2589
61. Lindholm C, Borjesson-Asp K, Zendjanchi K, etal. Long-term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008;35:826-833 (Pubitemid 351747123)
62. Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B cell malignancies. Curr Opin Invest Drugs 2008;9:1206-1215
63. Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD 22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74
64. Jacobi AM, Goldenberg DM, Hiepe F, et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008;67:450-457
65. Alarcon-Segovia D, Tumlin JA, Furie RA, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double blind, placebo-controlled study. Arth Rheum 2003;48:442-454 (Pubitemid 36278013)
66. Furie R, Cash JM, Cronin ME, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001;28:257-265 (Pubitemid 32165130)
67. Mosca M, Baldini C, Bombardieri S. LJP 394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Exp Opin Pharmacother 2007;8:873-879 (Pubitemid 46736459)
68. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470-80 • Important mechanistic study revealing the influence of CD40-CD40L interaction on development of lupus nephritis.
69. Cardiel MH, Tumlin JA, Furie RA, et al. LJP 394-90-09 Investigator consortium abetimus sodium for renal flare in systemic lupus erythematosus. Results of a randomized, controlled phase iii trial. Arthritis Rheum 2008;58:2470-2480
70. Furie RLJ, Merrill JT, Petri M, et al. LBSLO2 study group multiple SLE disease activity measures in a multi center phase 2 SLE trial demonstrate belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [Blys]) improves or stabilizes SLE activity. Ann Rheum Dis 2006;65:63
71. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Arthritis Rheum 2007;56:4142-4150
72. A study to evaluate the tolerability, safety and effectiveness of edratide in the treatment of lupus. Available from: http://clinicaltrials.gov/ ct2/show/NCT00203151?term=edratide&rank=1 .[Last accessed 7 May 2009]
73. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in SLE: results of a 12 month exploratory study [late breaking abstract L15]. 24-29 Oct 2008, San Francisco. ACR 2008
74. Quezada SA, Eckert M, Adeyi OA, et al. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arth Rheum 2003;48:2541-2554 (Pubitemid 37138671)
75. Gergely PJ, Grossman C, Niland B, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arth Rheum 2002;46:175-90 • Key mechanistic study revealing mitochondrial dysfunction in lupus T cells and their predisposition to proinflammtory cell death by necrosis.
76. Aringer M, Smolen JS. The role of tumor necrosis factor alpha in systemic lupus erythematosus. Arth Res Ther 2008;10:202 (Pubitemid 352044828)
77. Aringer M, Steiner G, Graninger WB, et al. Effects of short term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007;56:274-279 (Pubitemid 46106201)
78. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open label study. Arth Rheum 2004;50:3161-9 • Provocative study advocating TNF blockade for the treatment of systemic lupus.
79. Aringer M, Zimmermann C, Graninger W, et al. Anti TNF therapy of SLE is feasible and apparently effective. Arthritis Rheum 2003;48:S378
80. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-251 (Pubitemid 47067483)
81. Ronnblom L, Alm G. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 2003;5:68-75 (Pubitemid 36849752)
82. Kono D, Baccala R, Theofilopoulos A. Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor. Autoimmunity 2003;36:503-510 (Pubitemid 37498246)
83. Safety and tolerability of MEDI-545 in patients who have systemic lupus erythematosus. Available at: http://clinicaltrials.gov/ct2/show/NCT00299819? term=MEDI+545&rank=1. [Last accessed 7 May 2009]
84. Illei GG, Yarboro C, Shirota Y, et al. Tocilizumab (humanized anti IL-6 receptor monoclonal antibody) in patients with systemic lupus erythematosus: safety, tolerability and preliminary efficacy [late breaking abstract L20]. 12-15 Nov 2006, Washington, DC. ACR 2006
85. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006;2:619-626
86. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double blind phase II/III study EXPLORER [late breaking abstract L12]. 24-29 Oct 2008, San Francisco. ACR 2008
87. Sthoeger ZM, Dayan M, Zinger H, et al. The tolerogenic peptide MCDR1, down-regulates pathogenic cytokines and apoptosis and up-regulates TGF-bard regulatory T cells in PBMC of lupus patients. Lupus 2008;17:458
88. Llorente L, Richaud-Patin Y, Garcia-Padilla C, etal. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arth Rheum 2000;43:1790-800 • Important mechanistic study advocating the blockade of IL-10 signaling for the treatment of SLE.
89. Yanaba K, Bouaziz JD, Matsushita T, et al. TFB lymphocyte contributions to human autoimune disease. Immunol Rev 2008;223:284-299 (Pubitemid 351986191)
90. Mageed RA, Prud'homme GJ. Immunopathology and the gene therapy of lupus. Gene Therapy 2003;10:861-874
91. Cordeiro AC, Isenberg DA. Novel therapies in lupus - focus on nephritis. Acta Reumatol Port 2008;33:157-169
92. Ostendorf B, Iking-Konert C, Kurz K, et al. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005;64:630-633 (Pubitemid 40469097)
93. Wang Y, Hu Q, Madri JA, et al. Amelioration of lupus like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996;93:8563-8568 (Pubitemid 26269599)
94. Atkinson C, Qiao F, Song H, et al. Low dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 2008;180:1231-1238
95. Alexander JJ, Bao L, Jacob A, et al. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim Biophys Acta 2003;1639:169-176 (Pubitemid 37421424)
96. Perl A, Gergely P Jr, Nagy G, et al. Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. Trends Immunol 2004;25:360-367 (Pubitemid 38780952)
97. Fernandez DR, Telarico T, Bonilla E, et al. Activation of mTOR controls the loss of TCR in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol 2009;182:2063-2073
98. Nagy G, Koncz A, Perl A, etal. T cell activation induced mitochondrial hyperpolarization is mediated by Ca2 + and redox dependent production of nitric oxide. J Immunol 2003;171:5188-5197 (Pubitemid 37432803)
99. Fernandez DR, Perl A. Metabolic control of T-cell activation and death in SLE. Autoimmun Rev 2009;8:184-189
100. Anolik JH, Aringer M. New treatments for SLE: cell depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 2005;19:859-878 (Pubitemid 41258587)
101. Warner LM, Adams LM, Sehgal SN. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arth Rheum 1994;37:289-97 • Landmark paper showing clinical efficacy of mTOR blockade for the treatment of murine lupus.
102. Fernandez D, Bonilla E, Mirza N, et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxingin patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2983-8 • Landmark paper showing clinical efficacy of mTOR blockade for the treatment of patients with SLE.
103. Suwannaroj S, Lagoo A, Keisler D, Mcmurray RW. Antioxidants suppress mortality in the female NZBxNZW F1 mouse model of systemic lupus erythematosus. Lupus 2001;10:258-265 (Pubitemid 32332147)
104. IFIGENIA study group. High dose acetyl cysteine in pulmonary fibrosis. N Engl J Med 2005;353:2229-42 •• Double-blind, placebo-controlled study showing clinical efficacy and safety of acetyl cysteine for a chronic (auto)inflammatory disease.
105. Prospective study of rapamycin for the treatment of SLE (Rapamune). Available from: http://clinicaltrials.gov/ct2/show/NCT00779194?term= rapamune&rank=6. [Last accessed 7 May 2009]
106. Treatment of systemic lupus erythematosus (SLE) with N-acetylcysteine (NAC). Available from: http://clinicaltrials.gov/ct2/show/NCT00775476?term= syracuse&cond=lupus&rank=2. [Last accessed 7 May 2009]
107. Davis J Jr, Manzi S, Yarboro C, et al. Recombinant human DNase(rhDNase) in patients with lupus nephritis. Lupus 1999;8:68-76 (Pubitemid 29050221)
108. Chuzhin Y, Reddy B, Budhai L, et al. Prolonged survival in murine SLE by adenoviral mediated CTLA4Ig gene transfer. Arth Rheum 1998;41:S140
109. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006;85:147-156 (Pubitemid 43833013)
110. Gescuk BD, Davis JC. Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol 2002;14:515-521 (Pubitemid 34959978)
111. Ginzler E, Sharon E, Diamond H, Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 1975;18:27-34 •• Landmark article showing the benefit of chronic immunosuppression in SLE.
112. Moosig F, Zeuner R, Renk C, Schroder JO. IL-1 RA in refractory systemic lupus erythematosus. Lupus 2004;13:605-606 (Pubitemid 39145491)
113. Wallace DJ, Petri M, Olsen N, et al. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus [abstract 1315]. 6-11 Nov 2007 , Boston. ACR 2007